Anatara Lifesciences Ltd (ASX:ANR) chief executive officer Steven Lydeamore speaks to Proactive Investors about the healthcare company's renewed focus on human health, targeting the 11% of Australians affected by irritable bowel syndrome (IBS).
Lydeamore says the biotech firm's dietary supplement is unlike other gut health products at the pharmacy because it seeks to repair lining of the gut.
Anatara Lifesciences first came to prominence in developing a product to reduce diarrhoea in livestock.
Meet Cardinal Resources Ltd, Legend Mining Ltd and Danakali Ltd at our event, Melbourne , 16 July 2019. Register here »